Atopix Therapeutics Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
10
Active:7
Completed:3
Trial Phases
2 Phases
Phase 1:5
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (83.3%)Phase 2
1 (16.7%)Evaluation of Metabolic Profile of OC000459
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- Atopix Therapeutics, Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT02341521
- Locations
- 🇬🇧
Simbec Research, Merthyr Tydfil, Wales, United Kingdom
First in Man Evaluation of Single and Multiple Doses of Oral ATX2417
- First Posted Date
- 2014-12-15
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Atopix Therapeutics, Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT02316912
- Locations
- 🇬🇧
Simbec Research, Merthyr Tydfil, Glamorgan, United Kingdom
Effect of OC000459 on Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2013-12-05
- Last Posted Date
- 2018-03-26
- Lead Sponsor
- Atopix Therapeutics, Ltd.
- Target Recruit Count
- 142
- Registration Number
- NCT02002208
- Locations
- 🇬🇧
University of Sheffield, Sheffield, United Kingdom
News
No news found